文献速递头颈与中枢神经肿瘤

人工智能在脑肿瘤管理中的多模态数字工作流:诊断、治疗计划与纵向监测

Artificial intelligence for brain cancer management: multimodal digital workflows for diagnosis, treatment planning, and longitudinal monitoring.
PubMed 文献 · Eur J Cancer · 2026-08-14

该综述总结了人工智能(AI)与机器学习在神经肿瘤学诊断、分子分型、治疗计划和监测中的前沿进展。AI驱动的影像组学和深度学习在MRI与全切片图像肿瘤分割及分级中准确率超90%,液体活检可无创预测IDH/MGMT状态,混合CNN-Transformer模型用于免疫治疗分层和药物重定位,多模态整合可鉴别真性进展与假性进展。但数据稀缺、域偏移、黑箱模型、监管验证和工作流碎片化等挑战仍存,联邦学习、可解释AI和基础模型是潜在解决方案。

要点

  • AI影像组学与深度学习在MRI和全切片图像上肿瘤分割与分级准确率超90%。
  • 液体活检分析可无创预测IDH/MGMT状态,支持分子分型。
  • 混合CNN-Transformer模型助力免疫治疗分层和血脑屏障穿透药物重定位。

核心结论

  • AI与机器学习正在推动神经肿瘤学在诊断、分子分型、治疗计划和监测方面的变革,但数据、可解释性和监管等挑战仍需解决。

研究设计与样本

  • 本文为综述,总结了AI和机器学习在神经肿瘤学诊断、分子分型、治疗计划和监测中的前沿进展。

主要发现

  • AI驱动的影像组学和深度学习在MRI和全切片图像肿瘤分割与分级中准确率超过90%。
  • 液体活检分析可无创预测IDH/MGMT状态。
  • 增强现实引导切除可最大化肿瘤切除并保护表达皮层。
  • 混合CNN-Transformer模型用于免疫治疗分层和血脑屏障穿透药物重定位。
  • 多模态整合实时检测进展有助于区分真性进展与假性进展。

关键数值与推荐

  • AI驱动的影像组学和深度学习在MRI和全切片图像肿瘤分割与分级中准确率超过90%。

临床怎么用

  • AI工具可辅助脑肿瘤影像分割分级、液体活检分子分型、手术切除引导、治疗分层和进展监测。
  • 临床应用中需关注可解释AI和人类-AI协作框架以促进工具整合。

局限性

  • 罕见亚型数据稀缺和不平衡。
  • 成像变异性导致域偏移。
  • 黑箱模型行为削弱信任。
  • 监管要求前瞻性验证。
  • 工作流碎片化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Brain cancers, especially glioblastoma, remain among the deadliest adult cancers, with outcomes largely unchanged despite multimodal treatments. This review summarizes cutting-edge artificial intelligence (AI) and machine learning (ML) advances transforming neuro-oncology in diagnostics, molecular profiling, treatment planning, and monitoring. Key findings show AI-driven radiomics and deep learning (DL) reaching over 90% accuracy in tumour segmentation and grading from MRI and whole-slide images, non-invasive IDH/MGMT prediction through liquid biopsy (LB) analysis, and augmented reality-guided resection that maximizes tumour removal while safeguarding expressive cortex. Treatment planning benefits from hybrid Convolutional Neural Networks (CNN)-Transformer models for immunotherapy stratification and blood-brain barrier penetrant drug repurposing, while real-time progression detection via multimodal integration helps differentiate true progression from pseudoprogression. Despite these advances, significant challenges remain, including data scarcity and imbalance in rare subtypes, domain shift due to imaging variability, black-box model behaviour eroding trust, regulatory requirements for prospective validation, and workflow fragmentation. Emerging solutions include federated and transfer learning for scalable model development, explainable AI (such as SHapley Additive exPlanations (SHAP) and attention interpretation for vision transformers) to foster clinician-AI collaboration, and foundation models pretrained on large-scale neuro-oncology datasets to facilitate personalization. Achieving this potential will depend on harmonized multi-omics registries, strong ethical and regulatory governance, and deliberate human-AI collaboration frameworks to integrate these tools into precision neuro-oncology.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Saibaba G, Giwa O, Booth TC, et al. Artificial intelligence for brain cancer management: multimodal digital workflows for diagnosis, treatment planning, and longitudinal monitoring. Eur J Cancer. 2026. PMID: 42727528. doi:10.1016/j.ejca.2026.116991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。